Montag A & Associates Inc. boosted its position in Bristol-Myers Squibb Co (NYSE:BMY) by 13.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,563 shares of the biopharmaceutical company’s stock after buying an additional 1,877 shares during the quarter. Montag A & Associates Inc.’s holdings in Bristol-Myers Squibb were worth $954,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of BMY. Delphi Private Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at about $108,000. Atlantic Trust LLC bought a new stake in shares of Bristol-Myers Squibb during the 2nd quarter valued at about $111,000. Massey Quick Simon & CO. LLC grew its position in shares of Bristol-Myers Squibb by 523.5% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 1,492 shares during the last quarter. NuWave Investment Management LLC bought a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at about $119,000. Finally, Horan Capital Advisors LLC. bought a new stake in shares of Bristol-Myers Squibb during the 3rd quarter valued at about $122,000. Hedge funds and other institutional investors own 71.49% of the company’s stock.
Bristol-Myers Squibb stock opened at $66.10 on Thursday. Bristol-Myers Squibb Co has a 1 year low of $51.56 and a 1 year high of $70.05. The company has a quick ratio of 1.43, a current ratio of 1.55 and a debt-to-equity ratio of 0.59. The company has a market cap of $108,452.49, a PE ratio of 22.07, a price-to-earnings-growth ratio of 2.03 and a beta of 0.98.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.01. The business had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.35 billion. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The business’s revenue was up 3.9% on a year-over-year basis. During the same period last year, the firm posted $0.63 earnings per share. sell-side analysts forecast that Bristol-Myers Squibb Co will post 3.22 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 1st. Stockholders of record on Friday, April 6th will be issued a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 2.42%. The ex-dividend date of this dividend is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 271.19%.
A number of brokerages recently weighed in on BMY. Citigroup set a $78.00 price objective on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Friday, February 16th. Jefferies Group set a $72.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Monday, February 26th. TheStreet downgraded shares of Bristol-Myers Squibb from a “b” rating to a “c+” rating in a research report on Thursday, March 8th. DZ Bank downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, February 28th. Finally, Argus reaffirmed a “buy” rating and set a $66.43 price objective (down previously from $75.00) on shares of Bristol-Myers Squibb in a research report on Wednesday. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $66.79.
TRADEMARK VIOLATION NOTICE: “Bristol-Myers Squibb Co (BMY) Holdings Boosted by Montag A & Associates Inc.” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://ledgergazette.com/2018/03/22/bristol-myers-squibb-co-bmy-holdings-boosted-by-montag-a-associates-inc.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.